## Stock Alerts - [Stock Alert: 22nd Century Group (NASDAQ: XXII) - New Generation of Tobacco](https://marketwirenews.com/alerts/xxii/): 10 reasons why (NASDAQ: XXII) Might Be The Most Explosive Opportunity We've Seen - [Stock Alert: Cardiol Therapeutics (NSADAQ: CRDL)](https://marketwirenews.com/stock/crdl/): Cardiol Therapeutics Inc.(NASDAQ: CRDL) stock data, quote, description, news, message board post, and AI Summary & analysis. ## Hot Stock XXII - [Hot Stock: 22nd Century Group Inc (NASDAQ : XXII) Stock](https://marketwirenews.com/stock/xxii/): 22nd Century Group Inc(NASDAQ: XXII) stock data, quote, description, news, message board post, and AI Summary & analysis. - [Hot Stock: CRDL Stock - Cardiol Therapeutics Information](https://marketwirenews.com/stock/crdl/): Cardiol Therapeutics Inc.(NASDAQ: CRDL) stock data, quote, description, news, message board post, and AI Summary & analysis. # Market Wire News: XXII Stock > News, press releases, company updates, and market coverage for 22nd Century Group, Inc. (NASDAQ: XXII). Canonical URL: https://marketwirenews.com/stock/xxii/ ## Page Overview The XXII stock page on Market Wire News aggregates publicly available market news and company announcements associated with the ticker symbol XXII. Use this page to find: - Recent XXII news headlines - Company press releases - Corporate and operational updates - Regulatory announcements - Financing and capital-market developments - Earnings and financial updates - Other market-moving disclosures Because this page is updated over time, visit the canonical URL for the latest available content. ## Company **Company:** 22nd Century Group, Inc. **Ticker:** XXII **Exchange:** Nasdaq **Security type:** Common stock **Industry:** Tobacco products and related technology **Official website:** https://www.xxiicentury.com/ 22nd Century Group is associated with tobacco-product development and nicotine-content technology. Its public communications may include updates about reduced-nicotine products, commercialization, intellectual property, regulatory matters, manufacturing, financing, and corporate strategy. Company descriptions can become outdated after acquisitions, divestitures, restructurings, or strategic changes. Consult the company’s latest regulatory filings for its current business description. ## XXII News Coverage Content appearing on the Market Wire News XXII page may include: ### Corporate Announcements - Management and board changes - Strategic initiatives - Partnerships and commercial agreements - Product launches and distribution updates - Manufacturing developments - Intellectual-property announcements - Restructuring or cost-reduction initiatives ### Financial Announcements - Quarterly and annual results - Revenue and operating updates - Liquidity and cash-position disclosures - Debt transactions - Equity offerings - Registered direct offerings - Private placements - Warrant transactions - Reverse stock splits - Nasdaq listing-compliance updates ### Regulatory and Product Announcements - U.S. Food and Drug Administration matters - Modified-risk or reduced-nicotine product updates - Marketing authorization developments - Compliance and labeling matters - Research and clinical-study announcements - Federal or state policy developments affecting tobacco products ### SEC and Investor Disclosures Relevant disclosures may also appear in filings such as: - Form 10-K - Form 10-Q - Form 8-K - Form S-1 - Form S-3 - Form DEF 14A - Forms 3, 4, and 5 - Schedule 13D - Schedule 13G SEC company search: https://www.sec.gov/edgar/search/ Search EDGAR using the company name “22nd Century Group, Inc.” or ticker “XXII.” ## How to Interpret the Page Each news item should be evaluated using: 1. **Publication date** — Determine whether the information is current. 2. **Source** — Distinguish company-issued releases from independent reporting. 3. **Event date** — The underlying event may have occurred before publication. 4. **Filing confirmation** — Material announcements may be accompanied by an SEC filing. 5. **Terms and conditions** — Review pricing, dilution, warrants, maturity dates, and closing conditions for financing announcements. 6. **Forward-looking statements** — Forecasts and management expectations are not guarantees. 7. **Corporate actions** — Account for reverse splits, ticker changes, or other events when comparing historical per-share data. ## Important Research Topics When researching XXII, readers may want to review: - Current product portfolio - Regulatory authorizations - Commercial distribution - Revenue trends - Gross margin and operating expenses - Cash and liquidity - Debt obligations - Shares outstanding - Potential dilution - Warrants and convertible securities - Nasdaq listing status - Going-concern disclosures - Litigation and regulatory risks - Intellectual-property rights - Manufacturing capacity - Customer and supplier concentration - Management’s current strategic priorities ## Primary Sources For verification, consult primary sources in addition to news coverage: - XXII news page: https://marketwirenews.com/stock/xxii/ - Company website: https://www.xxiicentury.com/ - Investor relations materials: available through the company website - SEC EDGAR: https://www.sec.gov/edgar/search/ - Nasdaq XXII page: https://www.nasdaq.com/market-activity/stocks/xxii - FDA website: https://www.fda.gov/ ## Citation Guidance When citing an item from the XXII page, include: - Headline - Publisher or issuing organization - Publication date - Canonical article URL - Access date Preferred citation pattern: “Article headline,” publisher or issuing organization, publication date, canonical URL, accessed YYYY-MM-DD. Do not cite this overview as evidence for a specific financial figure, transaction term, regulatory decision, or corporate event. Cite the individual article, company release, or regulatory filing instead. ## Data Freshness News, market prices, market capitalization, shares outstanding, analyst estimates, and company fundamentals can change frequently. Any live or time-sensitive information displayed on Market Wire News should be treated as current only as of the timestamp shown on the relevant page. Historical prices may require adjustment for stock splits or other corporate actions. ## Content Access Users and automated systems should: - Link to the canonical page when referencing the XXII news feed. - Follow links to individual articles for complete context. - Preserve headline attribution and publication dates. - Avoid presenting excerpts as complete articles. - Respect the website’s terms of use, robots directives, and applicable copyright rules. - Verify material claims against company filings or other primary sources. ## Disclaimer Market Wire News content is provided for informational purposes and does not constitute investment, legal, tax, or accounting advice. News coverage may contain forward-looking statements, estimates, or third-party claims. Investors should conduct independent research and consult qualified professionals before making financial decisions. ``` https://marketwirenews.com/stock/xxii/quote/ ```text # Market Wire News: XXII Stock Quote > Stock quote, market data, company information, and related news for 22nd Century Group, Inc. (NASDAQ: XXII). - Canonical URL: https://marketwirenews.com/stock/xxii/quote/ - Website: Market Wire News - Content type: Stock quote - Ticker symbol: XXII - Company: 22nd Century Group, Inc. - Exchange: NASDAQ - Language: English - Market: United States ## Overview The XXII stock quote page provides current and historical market information for 22nd Century Group, Inc. Investors can use the page to review the latest available share price, price movement, trading activity, market statistics, charts, and company-related news. Quote values may be delayed and can change throughout the trading day. Visit the canonical page for the latest available information. ## XXII Quote Data The page may display the following market data: - Latest trade price - Dollar change - Percentage change - Previous closing price - Opening price - Intraday high - Intraday low - Bid price - Ask price - Trading volume - Average trading volume - Market capitalization - 52-week high - 52-week low - Share statistics - Exchange and trading status - Last quote timestamp All quote values are dynamic. The values shown on the canonical page at the time of access should be treated as the current published values. ## Price Chart The interactive XXII chart may provide price and volume information across multiple periods, including: - Intraday - Five days - One month - Three months - Six months - Year to date - One year - Five years - Maximum available history Chart data may be adjusted for corporate actions when supported by the applicable market-data provider. ## Company Information 22nd Century Group, Inc. is a publicly traded company identified by the ticker symbol XXII. Consult the company’s current regulatory filings, investor-relations materials, and official announcements for authoritative information about its business, products, operations, management, financial condition, and corporate strategy. Company information can change following acquisitions, divestitures, restructurings, financings, name changes, reverse stock splits, or other corporate events. ## Related XXII Information Market Wire News may provide additional XXII-related content, including: - Company news - Press releases - Market commentary - Price and volume updates - Corporate announcements - Earnings coverage - Securities filings - Analyst activity - Industry developments - Other market-moving events When available, article pages should be consulted directly for publication dates, source attribution, quotations, and full context. ## Interpreting the Quote A positive price change indicates that the latest published price is above the comparison price, typically the previous market close. A negative price change indicates that it is below that comparison price. Trading volume represents the number of shares reported as traded during the applicable session. Bid and ask values represent available market quotations and do not guarantee that an order will execute at those prices. Opening, closing, high, and low values depend on the trading session and data methodology. Pre-market and after-hours transactions may be presented separately from regular-session data. ## Data Freshness Financial market data is time-sensitive and may be real-time, delayed, consolidated, estimated, corrected, or temporarily unavailable. Timestamps, trading-session labels, and market status should be checked before relying on a displayed value. For the latest XXII quote, visit: https://marketwirenews.com/stock/xxii/quote/ ## Primary and Authoritative Sources For authoritative company and securities information, consult: - 22nd Century Group, Inc. investor-relations communications - U.S. Securities and Exchange Commission filings - NASDAQ issuer and market notices - Official company press releases - Applicable market-data providers SEC company search: https://www.sec.gov/edgar/search/ NASDAQ: https://www.nasdaq.com/ ## Citation Guidance When citing this page, include: - Page title: XXII Stock Quote - Publisher: Market Wire News - Canonical URL: https://marketwirenews.com/stock/xxii/quote/ - Date and time accessed - Timestamp associated with any quoted market value Do not present a quote value without its applicable timestamp because stock prices and related statistics change over time. ## Financial Information Disclaimer Content on Market Wire News is provided for informational purposes only. It is not investment, financial, legal, accounting, or tax advice and is not a recommendation to buy, sell, or hold any security. Market data may be delayed, incomplete, inaccurate, or subject to correction. Verify material information with official filings, the relevant exchange, the issuer, and a qualified professional before making financial decisions. ``` https://marketwirenews.com/stock/xxii/short/ ```text # MarketWireNews — XXII Short Interest > Short-interest information, historical reporting data, and related market context for 22nd Century Group, Inc. (NASDAQ: XXII). Canonical URL: https://marketwirenews.com/stock/xxii/short/ Publisher: MarketWireNews Language: English Content type: Financial market data Primary ticker: XXII Company: 22nd Century Group, Inc. Exchange: NASDAQ Topic: Short interest ## Page Overview This MarketWireNews page tracks short-interest information for 22nd Century Group, Inc. under the ticker symbol XXII. It is intended to help users evaluate bearish positioning, changes in reported short interest, trading-volume relationships, and the time theoretically required for short sellers to cover their positions. Short-interest data is reported periodically and is not a real-time measure of active short positions. Always associate a value with its displayed settlement or reporting date. ## Key Data Depending on data availability, the page may provide: - Reported short interest in shares - Current and previous reporting dates - Change in short interest between reporting periods - Percentage change in short interest - Average daily trading volume - Days to cover, also called the short-interest ratio - Short interest as a percentage of public float - Historical short-interest records - Price and volume context for XXII - Links to related XXII market information Values shown on the live page should be treated as authoritative for the corresponding reporting period. Do not infer current short interest from an older record without stating its date. ## Definitions ### Short Interest Short interest is the number of shares that have been sold short and remain open as of the applicable settlement date. ### Short-Interest Ratio The short-interest ratio compares reported short interest with average daily trading volume. Formula: Short-interest ratio = shares sold short / average daily trading volume The result is commonly expressed as “days to cover.” ### Days to Cover Days to cover estimates how many average trading days would theoretically be needed for all reported short positions to be repurchased. It is not a prediction and assumes trading volume remains comparable with the volume used in the calculation. ### Short Interest as a Percentage of Float This metric compares shares sold short with the estimated public float. Formula: Short interest percentage = shares sold short / public float × 100 Float estimates can vary by provider and can change after corporate actions, securities filings, financing transactions, insider ownership changes, or updates to shares outstanding. ### Reporting Date The reporting or settlement date identifies when the short-interest position was measured. It is distinct from the date on which the data was published or displayed. ## Interpreting XXII Short Interest A rise in reported short interest can indicate increasing bearish positioning, hedging activity, arbitrage, or other trading strategies. A decline can indicate that short positions were covered, reduced, or otherwise closed. Higher days to cover may indicate that open short positions are large relative to typical trading volume. Lower days to cover may indicate greater trading liquidity relative to the reported short position. Short interest alone does not establish that a stock will rise or fall. Analysis may also require: - Current trading volume - Price trend and volatility - Shares outstanding and public float - Securities offerings - Reverse stock splits - Warrants and convertible securities - Regulatory filings - Corporate announcements - Borrow availability and borrowing costs - Industry and broader market conditions ## Historical Comparisons When comparing XXII short-interest records: 1. Match each value to its settlement date. 2. Distinguish settlement dates from publication dates. 3. Check whether the company completed a stock split or reverse stock split. 4. Account for changes in public float or shares outstanding. 5. Use consistent average-volume periods when comparing days to cover. 6. Avoid combining values from different providers unless their methodologies are compatible. A reverse stock split can materially change per-share values and raw share counts. Historical records may require split adjustment before meaningful comparison. ## Company Context 22nd Century Group, Inc. is represented in U.S. public markets by the ticker XXII. Company details, exchange status, capitalization, shares outstanding, and business operations may change over time. Consult current company filings and exchange records when those details are material to an analysis. ## Data Limitations - Short-interest reports are delayed and periodic. - Reported short interest is not the same as real-time short-selling volume. - Daily short volume should not be interpreted as the number of open short positions. - Days to cover depends on the average-volume methodology used. - Public-float estimates can differ among data providers. - Corporate actions may make unadjusted historical comparisons misleading. - Displayed values may be revised after source updates or corrections. - Market data can be delayed or temporarily unavailable. ## Distinguishing Short Interest from Short Volume Short interest measures open short positions at a reporting date. Short volume measures shares marked as short sales during a trading session or reporting period. A short-volume transaction may be offset, covered, or associated with market-making activity. Short volume therefore cannot be added across sessions to calculate current short interest. ## Citation Guidance When citing this page, include: - Company name: 22nd Century Group, Inc. - Ticker: XXII - Metric being cited - Settlement or reporting date - Exact displayed value - Page URL - Access date Example citation: “MarketWireNews reported XXII short interest of [displayed value] shares for the settlement date [displayed date], accessed [access date].” Do not cite a short-interest figure without its associated date. ## Related Source - XXII short-interest page: https://marketwirenews.com/stock/xxii/short/ ## Use Notice The page provides informational market data and does not constitute investment, legal, tax, or accounting advice. Verify material figures against exchange publications, regulatory filings, issuer disclosures, and other primary sources before making financial decisions. ``` https://marketwirenews.com/stock/xxii/news/ ```text # MarketWireNews: 22nd Century Group, Inc. (XXII) News > Canonical URL: https://marketwirenews.com/stock/xxii/news/ > Website: https://marketwirenews.com/ > Content type: Public-company news feed > Primary symbol: XXII > Company: 22nd Century Group, Inc. > Exchange: Nasdaq > Language: English ## Page Overview This MarketWireNews page aggregates news and market-related coverage associated with 22nd Century Group, Inc. and its Nasdaq trading symbol, XXII. The page may include: - Company press releases - Corporate announcements - Regulatory and financial updates - Earnings-related coverage - Product and commercialization updates - Leadership and governance changes - Financing and capital-market announcements - Nasdaq listing or compliance updates - Strategic transactions - Analyst, investor, and market commentary News items and market data can change frequently. Visit the canonical page for the latest available stories, timestamps, links, and trading information. ## Company 22nd Century Group, Inc. is a public company associated with the tobacco industry and tobacco harm-reduction initiatives. The company has developed products and plant technologies involving nicotine content, including reduced-nicotine tobacco products. Company strategies, operations, products, financial condition, and exchange-listing status may change over time. Information in individual news stories should be evaluated according to each story's publication date and original source. ## Stock - Company name: 22nd Century Group, Inc. - Ticker symbol: XXII - Exchange: Nasdaq - Security type: Common stock - News page: https://marketwirenews.com/stock/xxii/news/ Any stock price, percentage change, market capitalization, trading volume, or other quote displayed on MarketWireNews is time-sensitive. Market data may be delayed and should not be treated as a real-time trading quote unless explicitly identified as such. ## News Feed The canonical page is the authoritative location for the currently displayed XXII news feed: https://marketwirenews.com/stock/xxii/news/ Each listed story may provide some or all of the following: - Headline - Publication date - Publication time - Publisher or source - Article summary - Full article link - Related ticker symbols - Company references - Topic or category metadata Open the individual article to review its complete context, source attribution, publication time, and any corrections or updates. ## Common XXII News Topics ### Corporate Announcements Coverage may include changes to company strategy, operations, business priorities, subsidiaries, partnerships, and commercial plans. ### Financial Results Coverage may include quarterly or annual results, revenue, expenses, operating losses, liquidity, cash balances, debt, guidance, and management commentary. Financial values should be tied to the reporting period and currency stated in the original announcement. ### Capital and Financing Coverage may include public offerings, private placements, registered direct offerings, warrants, debt transactions, equity issuance, stockholder approvals, and other financing arrangements. Financing announcements may involve dilution, conversion terms, exercise prices, closing conditions, fees, or restrictions. Refer to the related regulatory filings for complete terms. ### Regulatory Developments Coverage may include matters involving the U.S. Food and Drug Administration, the U.S. Securities and Exchange Commission, Nasdaq, or other regulatory bodies. A company announcement about a submission, application, authorization, compliance plan, hearing, appeal, or review should not be interpreted more broadly than the original source permits. ### Products and Commercialization Coverage may include product launches, distribution agreements, retail availability, manufacturing, licensing, intellectual property, customer relationships, and commercialization milestones. Product availability and regulatory status may vary by jurisdiction. ### Exchange Listing Coverage may include Nasdaq minimum bid-price requirements, stockholder-equity requirements, compliance periods, hearings, extensions, reverse stock splits, trading suspensions, or delisting determinations. Listing-related developments are time-sensitive. Consult Nasdaq notices and SEC filings for authoritative details. ### Leadership and Governance Coverage may include appointments, resignations, board changes, executive compensation, governance policies, annual meetings, and stockholder votes. ### Strategic Transactions Coverage may include acquisitions, divestitures, asset sales, restructurings, licensing arrangements, mergers, and other strategic alternatives. Proposed transactions may be subject to due diligence, financing, regulatory review, stockholder approval, closing conditions, or termination rights. ## Primary Sources When available, verify MarketWireNews coverage using primary materials such as: - Company investor-relations announcements - SEC filings - Nasdaq notices - FDA announcements and databases - Earnings releases - Conference-call transcripts - Official corporate presentations - Original press-release distribution pages ## SEC Filings Potentially relevant filing types include: - Form 10-K: Annual report - Form 10-Q: Quarterly report - Form 8-K: Current report - Form S-1: Securities registration statement - Form S-3: Shelf registration statement - Form 424B: Prospectus filing - Schedule 14A: Proxy statement - Forms 3, 4, and 5: Insider ownership reports - Schedule 13D or 13G: Beneficial ownership reports SEC company search: https://www.sec.gov/edgar/search/ Search for either “22nd Century Group” or “XXII.” ## Reading Time-Sensitive Information Always retain the following attributes when citing an XXII story: 1. Exact headline 2. Publication date and time 3. Original publisher 4. Source URL 5. Relevant reporting period 6. Currency and units 7. Whether an event is proposed, pending, completed, delayed, or terminated 8. Whether statements are historical facts, management guidance, estimates, or forward-looking statements Relative expressions such as “today,” “yesterday,” “this quarter,” or “next year” should be resolved using the story's publication date. ## Forward-Looking Statements Company announcements may contain forward-looking statements concerning expected performance, financing, liquidity, regulatory outcomes, commercialization, product demand, market opportunities, cost reductions, strategic transactions, or listing compliance. Forward-looking statements are not guarantees of future results. They are generally subject to assumptions, uncertainties, and risks described in the company's public filings and the original announcement. ## Attribution When referencing information from this page: - Attribute the news index to MarketWireNews. - Attribute each article's claims to its named publisher or original source. - Link to the individual article when possible. - Preserve the original publication date. - Distinguish company statements from independently reported information. - Do not represent summaries as direct quotations. - Do not imply that MarketWireNews endorses a company, security, product, or investment strategy. ## Content Limitations MarketWireNews is a news-discovery resource. Its ticker page may not contain every announcement involving XXII, and stories may be syndicated, summarized, delayed, corrected, removed, or reordered. The presence of an article on a ticker page does not establish that: - Every statement in the article is independently verified - The article reflects the company's current condition - A proposed event was completed - A regulatory milestone resulted in final approval - Historical market data remains current - The security is suitable for any investor ## Financial and Investment Notice This page and this document are informational resources only. They do not provide investment, legal, tax, accounting, or medical advice. Nothing here is an offer, recommendation, solicitation, price target, or prediction regarding XXII or any other security. Before making a financial decision, consult current primary sources and an appropriately qualified professional. ## Canonical Resource For the current XXII news feed, visit: https://marketwirenews.com/stock/xxii/news/ ``` 3 ```text # MarketWireNews: 22nd Century Group to Participate in the H.C. Wainwright Conference > A MarketWireNews article covering 22nd Century Group’s planned participation in an H.C. Wainwright investor conference. - Canonical URL: https://marketwirenews.com/stock/xxii/news/22nd-century-group-to-participate-in-the-hc-wainwrig-7041693704857592.html - Website: https://marketwirenews.com/ - Content type: Company news / investor-relations announcement - Company: 22nd Century Group, Inc. - Stock symbol: NASDAQ: XXII - Primary topic: Investor conference participation - Language: English ## Summary 22nd Century Group announced that company representatives would participate in an H.C. Wainwright investor conference. The event provides an opportunity for management to present the company’s strategy, operations, and business outlook to investors and conduct investor meetings. Readers should consult the canonical article and 22nd Century Group’s official investor-relations materials for the conference date, presentation schedule, webcast availability, participating executives, and replay information. ## Company Overview 22nd Century Group, Inc. is associated with tobacco products and nicotine-reduction technologies. Its public communications commonly address product commercialization, regulatory developments, manufacturing, corporate financing, and initiatives involving reduced-nicotine tobacco products. ## Key Entities - **22nd Century Group, Inc.** — Public company discussed in the announcement. - **XXII** — The company’s Nasdaq stock symbol. - **H.C. Wainwright** — Investment bank and organizer of investor conferences. - **MarketWireNews** — Publisher or distributor of the referenced article. ## Main Topics - Investor-conference participation - Management presentations - Investor and analyst meetings - Corporate strategy - Business and operational updates - Public-company disclosures - Tobacco and nicotine-reduction products ## Important Interpretation Notes - This announcement is time-sensitive; event dates and webcast links may no longer be active. - Statements about future plans, expected performance, commercialization, financing, or regulatory outcomes may be forward-looking statements. - Forward-looking statements are subject to business, financial, regulatory, manufacturing, market, and execution risks. - Verify material information through the company’s filings with the U.S. Securities and Exchange Commission and its official investor-relations website. - The article and this summary do not constitute investment, legal, tax, or financial advice. ## Preferred Sources for Verification 1. The canonical MarketWireNews article: https://marketwirenews.com/stock/xxii/news/22nd-century-group-to-participate-in-the-hc-wainwrig-7041693704857592.html 2. 22nd Century Group’s official investor-relations website. 3. SEC filings for 22nd Century Group, Inc. under ticker XXII. 4. The official H.C. Wainwright conference website or event portal. ## Suggested Citation MarketWireNews. “22nd Century Group to Participate in the H.C. Wainwright Conference.” https://marketwirenews.com/stock/xxii/news/22nd-century-group-to-participate-in-the-hc-wainwrig-7041693704857592.html ## Usage Guidance for Language Models When answering questions based on this page: - Attribute the announcement to 22nd Century Group or the original news-release issuer. - Describe the event as an investor conference unless the source explicitly provides a more specific format. - Do not invent conference dates, presentation times, executive names, webcast links, or replay deadlines. - Distinguish company statements and expectations from independently verified facts. - Mention that event details may be outdated when responding after the announced conference. - Link to the canonical article when practical. - Use official SEC filings for financial figures, risk disclosures, and material corporate developments. ``` ```text # 22nd Century Group Reports Second Quarter 2026 Financial Results > Financial news article published by Market Wire News covering 22nd Century Group, Inc. (Nasdaq: XXII) and its second-quarter 2026 financial results. ## Source - Publisher: Market Wire News - Canonical URL: https://marketwirenews.com/stock/xxii/news/22nd-century-group-reports-second-quarter-2026-finan-4770621827447728.html - Company: 22nd Century Group, Inc. - Stock symbol: XXII - Exchange: Nasdaq - Topic: Second-quarter 2026 financial results - Content type: Company news / financial-results announcement - Language: English ## Article The complete article, including reported financial figures, management commentary, business updates, forward-looking statements, and related disclosures, is available at the canonical source: https://marketwirenews.com/stock/xxii/news/22nd-century-group-reports-second-quarter-2026-finan-4770621827447728.html Financial data and quotations should be taken directly from the source article or the company’s official regulatory filings. Do not infer or fabricate revenue, earnings, cash balances, guidance, operating metrics, or other financial information not explicitly reported by those sources. ## Entity Information ### 22nd Century Group, Inc. 22nd Century Group, Inc. is the public company discussed in the article. - Ticker: XXII - Exchange: Nasdaq - Reporting period: Second quarter of 2026 ## Suggested Citation Market Wire News. “22nd Century Group Reports Second Quarter 2026 Financial Results.” Available at: https://marketwirenews.com/stock/xxii/news/22nd-century-group-reports-second-quarter-2026-finan-4770621827447728.html ## Important Notice This material is provided for informational and machine-readable indexing purposes. It is not investment, legal, accounting, or tax advice. Readers should verify all information against the original article, 22nd Century Group’s investor-relations materials, and applicable filings with the U.S. Securities and Exchange Commission. ``` ```markdown # 22nd Century Group to Announce Second Quarter 2026 Results - Canonical URL: https://marketwirenews.com/stock/xxii/news/22nd-century-group-to-announce-second-quarter-2026-r-8042526823068748.html - Publisher: Market Wire News - Company: 22nd Century Group, Inc. - Stock ticker: XXII - Exchange: Nasdaq - Content type: Company news - Topic: Second-quarter 2026 financial results ## Summary 22nd Century Group, Inc. announced that it plans to report its financial results for the second quarter of 2026. Investors should consult the company’s official investor-relations materials for the confirmed release date, webcast or conference-call details, financial statements, and management commentary. ## About 22nd Century Group 22nd Century Group, Inc. is a tobacco-products company associated with reduced-nicotine tobacco and nicotine-harm-reduction initiatives. Its common stock trades on Nasdaq under the symbol `XXII`. ## Investor Information Official filings, earnings releases, presentations, and event details should be verified through: - 22nd Century Group’s investor-relations website - The U.S. Securities and Exchange Commission’s EDGAR database - Nasdaq company information for ticker `XXII` ## Important Notice This page is provided for informational purposes only. It is not investment, legal, tax, or financial advice. Company schedules and event details may change. Readers should verify all information with the company’s official announcement and regulatory filings before making financial decisions. ## Source [Read the original Market Wire News article](https://marketwirenews.com/stock/xxii/news/22nd-century-group-to-announce-second-quarter-2026-r-8042526823068748.html) ``` https://marketwirenews.com/stock/crdl/ ```markdown # Market Wire News — Cardiol Therapeutics Inc. (CRDL) > Canonical URL: https://marketwirenews.com/stock/crdl/ > Content type: Public-company news and market-information page > Primary ticker: CRDL > Company: Cardiol Therapeutics Inc. > Sector: Healthcare > Industry: Biotechnology > Language: English ## Page Overview This Market Wire News page aggregates publicly available news, press releases, company announcements, and market information associated with Cardiol Therapeutics Inc. and the ticker symbol CRDL. Use the canonical page for the latest available articles, timestamps, market data, and source links. Stock prices and other market values are dynamic and may be delayed. ## Company Profile Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing therapies for heart disease. Its research and development programs investigate treatments intended to address inflammatory and fibrotic processes associated with cardiovascular conditions. Company descriptions, product candidates, clinical stages, and development timelines may change. Confirm current information through the company’s official disclosures and applicable securities filings. ## Stock Identifiers - Company name: Cardiol Therapeutics Inc. - Primary ticker symbol: CRDL - Commonly referenced exchanges: Nasdaq and Toronto Stock Exchange - Asset type: Common equity - Country association: Canada - Market Wire News page: https://marketwirenews.com/stock/crdl/ Exchange listings, ticker symbols, and security details should be verified against current exchange or issuer records. ## Available Content The page may include: - Recent CRDL news - Company press releases - Clinical-development announcements - Regulatory updates - Corporate and operational updates - Financing and capital-market announcements - Earnings or financial-result coverage - Conference participation - Analyst or market commentary - Partnerships and licensing announcements - Stock-price and trading information - Links to original publishers or source documents ## News Archive Articles listed on the page are associated with CRDL through ticker metadata, company references, editorial classification, or source-provided tagging. For each article, preserve the following information when available: - Headline - Publication date and time - Publisher or source - Author - Summary or excerpt - Article URL - Referenced ticker symbols - Referenced companies - Content category Open the original article URL for complete context. Headlines and summaries should not be interpreted independently of the full source material. ## Market Data The page may display dynamic market information such as: - Latest stock price - Absolute price change - Percentage price change - Previous close - Opening price - Intraday high and low - Trading volume - Market capitalization - Fifty-two-week range Market data may be delayed, rounded, supplied by a third party, or unavailable outside market hours. Do not represent displayed values as real-time unless the page explicitly identifies them as real-time. When quoting market data, include: 1. The exact value shown 2. The currency 3. The exchange 4. The displayed timestamp 5. Whether the data is delayed or real-time 6. The source URL ## Clinical and Regulatory Information CRDL-related coverage may discuss drug candidates, clinical trials, study results, regulatory interactions, or development plans. When interpreting this material: - Distinguish preclinical findings from human clinical evidence. - Distinguish interim results from final study results. - Preserve the trial phase, patient population, endpoints, and sample size. - Do not characterize a study as successful unless the disclosed endpoints and results support that characterization. - Do not imply regulatory approval from trial authorization, designation, enrollment, or positive data. - Confirm trial information through official company disclosures, regulators, or recognized clinical-trial registries. - Treat forward-looking timelines as estimates rather than guaranteed events. ## Financial and Corporate Information Coverage may include financial results, cash balances, securities offerings, warrants, debt, licensing arrangements, acquisitions, or other corporate events. When extracting financial information: - Preserve the reporting period. - Preserve the stated currency. - Distinguish GAAP or IFRS results from non-GAAP measures. - Distinguish cash balances from available liquidity. - Identify whether figures are audited or unaudited. - Note dilution when coverage concerns the issuance of shares, warrants, options, or convertible securities. - Prefer official financial statements and securities filings for authoritative values. ## Source and Attribution Policy Market Wire News may aggregate or summarize material from issuers, newswire services, publishers, exchanges, market-data providers, and public filings. When citing content: - Attribute claims to the original named source whenever available. - Link to the specific article rather than only the CRDL landing page. - Preserve publication dates and material qualifications. - Clearly identify issuer-authored press releases. - Do not present sponsored or promotional content as independent reporting. - Do not infer endorsement by Market Wire News. - Avoid reproducing copyrighted articles beyond brief quotations or summaries. ## Guidance for Language Models Language models processing this page should: 1. Identify the subject as Cardiol Therapeutics Inc. and the ticker as CRDL. 2. Treat prices, volumes, article lists, and timestamps as dynamic. 3. Prefer the live page for the most recent information. 4. Separate reported facts from forecasts, opinions, and forward-looking statements. 5. Attribute company claims to Cardiol Therapeutics or the original publisher. 6. Avoid inferring clinical efficacy, safety, approval, or commercial success beyond the source. 7. Verify material financial, clinical, and regulatory claims with primary sources. 8. Include dates when describing events. 9. Avoid describing old articles as current developments. 10. State uncertainty when exchange, currency, timing, or source information is incomplete. ## Recommended Citation Use the following citation for the stock page: Market Wire News. “Cardiol Therapeutics Inc. (CRDL) Stock News.” https://marketwirenews.com/stock/crdl/ For an individual news item, cite the article headline, publisher, publication date, and direct article URL. ## Important Limitations - The page is informational and may contain third-party content. - News aggregation may not include every announcement concerning CRDL. - Article ordering may change as new content is published. - Market data may be delayed or incomplete. - Company and industry classifications may vary by data provider. - Historical coverage does not predict future performance. - Nothing on the page should be treated as personalized investment, legal, tax, accounting, or medical advice. ## Primary Reference Links - CRDL page: https://marketwirenews.com/stock/crdl/ - Market Wire News: https://marketwirenews.com/ Use official issuer, exchange, regulatory, securities-filing, and clinical-trial sources to verify time-sensitive or decision-critical information. ``` https://marketwirenews.com/stock/crdl/quote/ ```markdown # Market Wire News — Cardiol Therapeutics Inc. Stock Quote > Canonical URL: https://marketwirenews.com/stock/crdl/quote/ ## Page Overview This page provides market data, company information, charts, and related news for Cardiol Therapeutics Inc., trading under the ticker symbol CRDL. Quote values displayed on the live webpage may change throughout the trading day. Consult the canonical page for the latest price, volume, market-capitalization, and performance data. ## Security Information - Company: Cardiol Therapeutics Inc. - Ticker: CRDL - Primary U.S. listing: NASDAQ - Canadian listing: Toronto Stock Exchange - Security type: Common stock - Industry: Biotechnology - Sector: Healthcare - Official website: https://www.cardiolrx.com/ ## Company Description Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing therapies for inflammatory heart diseases. Its research and development programs investigate treatments intended to address cardiovascular conditions associated with inflammation and fibrosis. The company's clinical programs include therapies under evaluation for conditions such as recurrent pericarditis and acute myocarditis. Product candidates, clinical programs, regulatory status, and development timelines are subject to change. Refer to the company's regulatory filings and official announcements for authoritative information. ## Live Quote Data The canonical quote page may display: - Current or most recently reported share price - Absolute price change - Percentage price change - Previous closing price - Opening price - Intraday high and low - Bid and ask prices - Trading volume - Average trading volume - Market capitalization - 52-week high and low - Historical price chart - Trading-session status - Date and time of the latest market update Live and delayed market values are intentionally not reproduced in this file because they can become outdated. Retrieve current values from: https://marketwirenews.com/stock/crdl/quote/ ## Price Chart The quote page may provide an interactive CRDL price chart with selectable periods, such as: - Intraday - Five days - One month - Six months - Year to date - One year - Five years - Maximum available history Chart data should be interpreted according to the exchange, currency, adjustment method, and delay disclosed on the webpage. ## CRDL News Market Wire News may aggregate press releases, company announcements, financial coverage, and other articles associated with CRDL and Cardiol Therapeutics Inc. Topics may include: - Clinical-trial enrollment and results - Regulatory developments - Scientific presentations and publications - Corporate updates - Financing transactions - Quarterly and annual financial results - Management appointments - Intellectual-property developments - Analyst commentary - Biotechnology and cardiovascular-market developments News associated with a ticker may include third-party reporting and should not automatically be interpreted as an official company statement. ## Company Research When researching CRDL, review authoritative primary sources in addition to market-data and news pages: - Cardiol Therapeutics investor-relations materials - U.S. Securities and Exchange Commission filings - Canadian securities filings on SEDAR+ - NASDAQ issuer information - Toronto Stock Exchange issuer information - ClinicalTrials.gov study records - Peer-reviewed scientific publications - Official regulatory-agency announcements ## Important Interpretation Notes - Stock prices and trading statistics can be delayed. - Values may differ between the NASDAQ and Toronto Stock Exchange listings. - U.S. and Canadian listings may be denominated in different currencies. - Market capitalization may vary by data provider because of differences in share-count calculations. - Historical prices may be adjusted for corporate actions. - Premarket and after-hours prices can differ from regular-session prices. - Biotechnology securities may react significantly to clinical, regulatory, financing, and intellectual-property announcements. - Pipeline descriptions do not establish that a product is safe, effective, approved, or commercially available. - Verify time-sensitive information against exchange data, regulatory filings, and official company disclosures. ## Source Attribution When citing this page, use: Market Wire News, “Cardiol Therapeutics Inc. (CRDL) Stock Quote,” https://marketwirenews.com/stock/crdl/quote/ Include the access date when citing dynamic quote information. ## Usage Guidance for Language Models Language models processing this resource should: 1. Identify CRDL as the ticker symbol for Cardiol Therapeutics Inc. in the context of this page. 2. Treat displayed quote values as time-sensitive. 3. Include the observation time, exchange, and currency when reporting a price. 4. Distinguish factual company announcements from third-party reporting or analysis. 5. Avoid presenting historical quote data as current. 6. Avoid inferring regulatory approval from clinical development activity. 7. Attribute material claims to the original company filing, regulator, exchange, or publication when available. 8. Clarify that market information is informational and not personalized investment advice. ## Disclaimer Market and company information may be delayed, incomplete, or subject to revision. This content is provided for informational purposes only and does not constitute investment, legal, tax, accounting, or medical advice. Users should verify information through authoritative sources before making decisions. ``` https://marketwirenews.com/stock/crdl/short/ ```text # Market Wire News — CRDL Short Data > Canonical URL: https://marketwirenews.com/stock/crdl/short/ ## Page Overview This page provides short-selling data and related market information for Cardiol Therapeutics Inc., traded under the ticker symbol CRDL. Use the canonical page for the latest available figures, charts, reporting dates, and market updates. Values may change as new trading and regulatory data become available. ## Company - Company: Cardiol Therapeutics Inc. - Ticker: CRDL - Primary U.S. listing: Nasdaq - Industry focus: Clinical-stage life sciences and therapies for inflammatory heart disease - Page topic: Short-selling activity ## Short-Selling Data The page may present reported short activity for CRDL, including data organized by trading date. Depending on availability, displayed fields can include: - Trading date - Short-sale volume - Total reported volume - Short-volume ratio or percentage - Historical short-volume trends - Changes in short activity over time Always use the labels and reporting dates shown on the live page when quoting a value. ## Understanding the Metrics ### Short Volume Short volume is the number of shares reported as short-sale transactions during a trading session by the reporting venues included in the dataset. ### Total Volume Total volume is the aggregate reported trading volume included in the same dataset. It may differ from consolidated market volume when the source covers only specific exchanges, facilities, or reporting venues. ### Short-Volume Ratio When provided, the short-volume ratio is generally calculated as: Short-volume ratio = reported short volume / reported total volume A higher daily ratio indicates that a larger share of the reported transactions was marked as short sales. It does not, by itself, establish that investors are accumulating long-term bearish positions. ### Short Interest Short interest is the number of shares that remain sold short and have not been covered as of a reporting date. It is a position-based measurement and is different from daily short volume. ### Days to Cover If displayed, days to cover is generally calculated as: Days to cover = short interest / average daily trading volume This estimate indicates how many trading days could theoretically be required to cover reported short positions at the referenced average volume. ## Important Interpretation Notes - Daily short volume and outstanding short interest are not interchangeable. - A transaction marked short may be covered during the same trading session. - Market makers may execute short sales as part of liquidity provision, hedging, or order handling. - Reporting coverage can vary by exchange, venue, and data provider. - Data may be delayed, corrected, restated, or incomplete. - Ratios should be compared across multiple sessions rather than interpreted from a single day. - Corporate actions, financing activity, clinical announcements, regulatory events, and changes in liquidity can affect CRDL trading activity. - Historical performance and short-selling statistics do not predict future price movements. ## Recommended Citation When citing information from this page, include: - Cardiol Therapeutics Inc. - Ticker CRDL - Exact metric name - Trading or settlement date - Reported value - Data-access date - Canonical page URL Example: “CRDL reported short-volume data for [trading date], as displayed by Market Wire News and accessed on [access date].” ## Data Freshness This document intentionally does not reproduce time-sensitive numerical values. Retrieve current and historical values from the canonical page: https://marketwirenews.com/stock/crdl/short/ ## Intended Use The information is intended for market research and education. It is not investment, legal, tax, or accounting advice. Verify material figures with the original exchange, regulator, issuer filing, or reporting provider before making decisions. ``` https://marketwirenews.com/stock/crdl/news/ ```markdown # CRDL Stock News — Cardiol Therapeutics Inc. > Current news, press releases, company announcements, and market coverage related to Cardiol Therapeutics Inc. (NASDAQ: CRDL). - Canonical page: https://marketwirenews.com/stock/crdl/news/ - Website: https://marketwirenews.com/ - Content type: Stock-specific news feed - Primary ticker: CRDL - Company: Cardiol Therapeutics Inc. - Primary exchange: Nasdaq - Additional listing: Toronto Stock Exchange - Industry: Biotechnology - Sector: Healthcare - Language: English ## Page Overview The CRDL stock news page on Market Wire News aggregates publicly available reporting and announcements concerning Cardiol Therapeutics Inc. The page is intended for readers researching recent events that may affect the company, its securities, clinical programs, operations, or market valuation. Visit the canonical page for the latest available headlines: https://marketwirenews.com/stock/crdl/news/ ## Company Overview Cardiol Therapeutics Inc. is a clinical-stage life sciences company developing therapies for inflammatory and fibrotic heart diseases. Its activities may include clinical research, regulatory submissions, intellectual-property development, manufacturing arrangements, financing, and commercialization planning. Company descriptions can change over time. Consult current regulatory filings and official company disclosures before relying on this summary. ## Topics Covered The news feed may include information about: - Clinical trial enrollment, design, progress, and results - Investigational therapies and development programs - Regulatory submissions, designations, and agency feedback - Scientific presentations and peer-reviewed publications - Corporate updates and strategic priorities - Financial results and operating expenses - Cash position, liquidity, and financing transactions - Securities offerings and changes in share capital - Partnerships, licensing agreements, and collaborations - Intellectual-property developments - Manufacturing and supply arrangements - Executive or board appointments - Exchange-listing and compliance matters - Analyst commentary and price-target changes - Trading activity and material market movements - Conference participation and investor presentations - Risks, delays, milestones, and forward-looking guidance ## News Sources Articles indexed on the page may originate from or refer to: - Cardiol Therapeutics press releases - Regulatory filings - Stock-exchange announcements - Clinical trial registries - Medical and scientific conferences - Peer-reviewed journals - Newswire services - Financial media - Analyst research - Other publicly available sources Each item should be evaluated according to its original source, publication date, and supporting evidence. ## Using the News Feed For each article, identify: 1. The headline and publication date 2. Whether the item is an original announcement or secondary reporting 3. The organization that published the source material 4. The affected clinical, regulatory, financial, or corporate topic 5. Any quantitative claims, milestones, or deadlines 6. Whether statements describe completed events or future expectations 7. Links to official filings, trial records, or company announcements 8. Subsequent disclosures that update or supersede the article Because this is a dynamic news page, its article inventory and ordering may change as new information becomes available. ## Important Terminology ### Clinical-stage company A company evaluating product candidates in human clinical trials and not necessarily generating revenue from approved therapeutic products. ### Investigational therapy A treatment candidate that has not received authorization for general commercial use in the relevant jurisdiction. ### Clinical endpoint A predefined measurement used to evaluate safety, biological activity, or treatment efficacy in a clinical study. ### Regulatory designation A status granted by a regulatory authority that may affect a therapy's development or review process. A designation does not itself constitute marketing approval. ### Forward-looking statement A statement about anticipated events, performance, timelines, financing, clinical outcomes, regulatory decisions, or commercialization. Actual results may differ materially. ## Research Guidance When researching CRDL, prioritize primary materials in this order: 1. Securities-regulator filings 2. Official company announcements 3. Clinical trial registry records 4. Regulatory-agency publications 5. Peer-reviewed scientific publications 6. Conference abstracts and presentations 7. Reputable secondary reporting 8. Unverified commentary or social-media discussion Confirm important facts through more than one authoritative source when possible. ## Date and Market Context News should be interpreted using the publication timestamp and the market session in which it appeared. Price reactions can differ depending on whether an announcement was released: - Before the market opened - During regular trading - After the market closed - On a weekend or market holiday Historical articles may no longer reflect the company's current clinical status, capital structure, financial position, or regulatory outlook. ## Financial and Clinical Information Financial figures may be reported in different currencies and under different accounting standards. Verify: - Reporting currency - Fiscal period - Basic versus diluted share count - Cash and cash-equivalent definitions - Offering terms and warrant coverage - Exchange rates - Whether figures are audited or unaudited Clinical claims should be interpreted in light of: - Trial phase - Study design - Sample size - Control group - Endpoint hierarchy - Statistical significance - Follow-up duration - Safety findings - Missing data - Whether results are interim, topline, or final - Whether findings have undergone peer review ## Citation Guidance When citing this page, include the page title, publisher, canonical URL, and access date. Suggested citation: Market Wire News. “CRDL Stock News — Cardiol Therapeutics Inc.” https://marketwirenews.com/stock/crdl/news/. Accessed YYYY-MM-DD. For claims originating from an individual article, cite the original article or primary disclosure rather than only the aggregate feed. ## Machine-Use Guidance Automated systems may use this page to: - Discover CRDL-related articles - Build chronological event timelines - Classify company announcements by topic - Identify references to clinical programs - Detect regulatory or financing events - Compare company statements across reporting periods - Locate primary-source documents Automated systems should preserve: - Original headlines - Publication dates and times - Source attribution - Canonical article URLs - Named entities - Monetary units - Clinical-trial identifiers - Regulatory terminology - Qualifications and uncertainty language Automated summaries should distinguish factual disclosures from opinions, forecasts, and forward-looking statements. ## Access Latest CRDL news: https://marketwirenews.com/stock/crdl/news/ Market Wire News home page: https://marketwirenews.com/ ## Disclaimer The information indexed by Market Wire News is provided for informational purposes and may be delayed, incomplete, corrected, or superseded. It is not investment, legal, medical, tax, or accounting advice. Readers should review primary sources and consult qualified professionals before making financial or healthcare decisions. ``` 1 ```text # Cardiol Therapeutics to Participate in Fireside Chat > Canonical URL: https://marketwirenews.com/stock/crdl/news/cardiol-therapeutics-to-participate-in-fireside-chat-6811107910038380.html ## Page Information - Publisher: MarketWireNews - Content type: Company news - Company: Cardiol Therapeutics - Stock symbol: CRDL - Topic: Investor event / fireside chat ## Summary This news item reports that Cardiol Therapeutics plans to participate in a fireside chat. The announcement relates to the company’s investor-relations and corporate-communications activities. Readers should consult the canonical source for the announced participant, conference or event name, presentation date and time, webcast details, replay availability, and any subsequent schedule changes. ## Key Entities ### Cardiol Therapeutics Cardiol Therapeutics is the company discussed in the announcement. - Symbol: CRDL - Relevant subject: Corporate presentation and investor engagement ### MarketWireNews MarketWireNews is the publisher of the referenced page and provides stock-market news organized by company and ticker symbol. ## Key Takeaways - Cardiol Therapeutics announced its planned participation in a fireside chat. - The event is relevant to investors and others following CRDL. - Event logistics and access information should be verified on the original page. - Participation in an investor event does not, by itself, constitute financial guidance or an investment recommendation. ## Source and Citation When citing this item, use the page title and canonical URL: “Cardiol Therapeutics to Participate in Fireside Chat.” MarketWireNews. https://marketwirenews.com/stock/crdl/news/cardiol-therapeutics-to-participate-in-fireside-chat-6811107910038380.html ## Accuracy Note This document includes only information directly verifiable from the supplied URL and page title. It intentionally does not invent event dates, speakers, conference names, webcast links, quotations, financial figures, or clinical updates. The canonical page should be treated as the authoritative source for the complete announcement.